Compare Home Depot Inc (HD) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Home Depot Inc vs Tango Therapeutics Inc. — how do they compare? Home Depot Inc trades at $297 (market cap $293.24B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Home Depot Inc is far larger — about 78.2× Tango Therapeutics Inc.'s market cap, and Home Depot Inc pays a 3.17% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Home Depot Inc for 139 Days and Tango Therapeutics Inc. for 0 Days on average.
| HD | TNGX | |
|---|---|---|
Market Cap | $293.24B | $3.75B |
Volume | 4,521,013 | 9,619,106 |
Sector | Consumer Cyclical | Health |
52-Week High | $391.90 | $32.90 |
52-Week Low | $281.15 | $7.50 |
Typical Hold Time | 139 Days | 0 Days |
Enterprise Value | $353.72B | $2.77B |
Dividend Yield | 3.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Home Depot (HD) trades at $295.51, up 1.68% with strong earnings momentum after beating Q2 2026 EPS estimates. The stock shows bearish technical signals but maintains solid fundamentals with $159.51B revenue and 8.41% net margin. Recent institutional activity shows mixed positioning while analyst consensus remains bullish with a $379.93 price target.
HD offers value with reasonable valuation multiples (P/E 20.57) and consistent profitability, though margin compression and housing market sensitivity pose risks. The 58.73% buy rating from analysts suggests upside potential, but investors should monitor Pro segment performance amid weakening big-ticket demand.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Home Depot Inc
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
